Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 47.39
IDRA's Cash to Debt is ranked higher than
71% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. IDRA: 47.39 )
IDRA' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 47.39

Equity to Asset 0.84
IDRA's Equity to Asset is ranked higher than
85% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IDRA: 0.84 )
IDRA' s 10-Year Equity to Asset Range
Min: -1.31   Max: 0.9
Current: 0.84

-1.31
0.9
F-Score: 2
Z-Score: 17.42
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -53084.93
IDRA's Operating margin (%) is ranked lower than
53% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. IDRA: -53084.93 )
IDRA' s 10-Year Operating margin (%) Range
Min: -53084.93   Max: 941.09
Current: -53084.93

-53084.93
941.09
Net-margin (%) -52934.25
IDRA's Net-margin (%) is ranked lower than
53% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. IDRA: -52934.25 )
IDRA' s 10-Year Net-margin (%) Range
Min: -52934.25   Max: 57.33
Current: -52934.25

-52934.25
57.33
ROE (%) -75.53
IDRA's ROE (%) is ranked higher than
59% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. IDRA: -75.53 )
IDRA' s 10-Year ROE (%) Range
Min: -302.28   Max: 194.96
Current: -75.53

-302.28
194.96
ROA (%) -67.15
IDRA's ROA (%) is ranked higher than
57% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. IDRA: -67.15 )
IDRA' s 10-Year ROA (%) Range
Min: -181.34   Max: 63.38
Current: -67.15

-181.34
63.38
ROC (Joel Greenblatt) (%) -6184.49
IDRA's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. IDRA: -6184.49 )
IDRA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11798.05   Max: 9024.79
Current: -6184.49

-11798.05
9024.79
EBITDA Growth (3Y)(%) -17.60
IDRA's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. IDRA: -17.60 )
IDRA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -69.8   Max: 4.8
Current: -17.6

-69.8
4.8
EPS Growth (3Y)(%) -23.00
IDRA's EPS Growth (3Y)(%) is ranked higher than
64% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IDRA: -23.00 )
IDRA' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.7   Max: 4.6
Current: -23

-62.7
4.6
» IDRA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IDRA Guru Trades in Q4 2013

Steven Cohen 10,000 sh (New)
Jean-Marie Eveillard Sold Out
Jim Simons Sold Out
» More
Q1 2014

IDRA Guru Trades in Q1 2014

Paul Tudor Jones 23,810 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

IDRA Guru Trades in Q2 2014

Paul Tudor Jones 12,055 sh (-49.37%)
» More
Q3 2014

IDRA Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IDRA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.20
IDRA's P/B is ranked higher than
59% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. IDRA: 7.20 )
IDRA' s 10-Year P/B Range
Min: 0.83   Max: 548
Current: 7.2

0.83
548
P/S 3766.93
IDRA's P/S is ranked lower than
60% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. IDRA: 3766.93 )
IDRA' s 10-Year P/S Range
Min: 0   Max: 3903
Current: 3766.93

0
3903
Current Ratio 6.02
IDRA's Current Ratio is ranked higher than
78% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. IDRA: 6.02 )
IDRA' s 10-Year Current Ratio Range
Min: 0.13   Max: 10.07
Current: 6.02

0.13
10.07
Quick Ratio 6.02
IDRA's Quick Ratio is ranked higher than
79% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. IDRA: 6.02 )
IDRA' s 10-Year Quick Ratio Range
Min: 0.13   Max: 10.07
Current: 6.02

0.13
10.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.50
IDRA's Price/Net Cash is ranked higher than
81% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 107.00 vs. IDRA: 9.50 )
IDRA' s 10-Year Price/Net Cash Range
Min: 2.16   Max: 77.06
Current: 9.5

2.16
77.06
Price/Net Current Asset Value 9.50
IDRA's Price/Net Current Asset Value is ranked higher than
79% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. IDRA: 9.50 )
IDRA' s 10-Year Price/Net Current Asset Value Range
Min: 2.08   Max: 56.96
Current: 9.5

2.08
56.96
Price/Tangible Book 7.20
IDRA's Price/Tangible Book is ranked higher than
71% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. IDRA: 7.20 )
IDRA' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 413.2
Current: 7.2

1.9
413.2
Earnings Yield (Greenblatt) -11.00
IDRA's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IDRA: -11.00 )
IDRA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11   Max: 164993.3
Current: -11

-11
164993.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXXA.Germany,
Idera Pharmaceuticals, Inc. was incorporated in Delaware on May 25, 1989. The Company is a clinical stage biotechnology company engaged in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors, or TLRs. The Company is also evaluating gene silencing oligonucleotides, or GSOs, which inhibit the production of disease-associated proteins by targeting RNA. TLRs are specific receptors present in immune system cells. Using a chemistry-based approach, the Company has created synthetic DNA- and RNA-based compounds that are targeted to TLRs 3, 7, 8, and 9. A TLR agonist is a compound that stimulates an immune response through the targeted TLR. A TLR antagonist is a compound that blocks activation of an immune response through the targeted TLR. Drug candidates are compounds that the Company is developing and that have not been approved for any commercial use. The Company is focusing its internal development efforts on TLR-targeted clinical candidates for autoimmune and inflammatory diseases and cancer, and on the advancement of its GSO technology platform. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It is conducting nonclinical studies of IMO-8400 to support the submission of an Investigational New Drug Application, or IND, for IMO-8400. Its GSOs are single-stranded RNA or DNA constructs that are complementary to targeted mRNA sequences of therapeutic interest. In preclinical studies, the Company's GSOs has inhibited in vivo gene expression without requiring a delivery enhancement technology. In addition to its clinical programs in autoimmune and inflammatory diseases and in cancer, the Company has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants. The principal competitor developing TLR-targeted compounds for autoimmune diseases is Dynavax Technologies Corporation, or Dynavax, with its collaborator, GlaxoSmithKline plc, or GlaxoSmithKline. The testing, manufacturing, labeling, advertising, promotion, export, and marketing of its products are subject to extensive regulation by governmental authorities in Europe, the United States, and elsewhere throughout the world.
» More Articles for IDRA

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
Idera Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides Pipeline Update Aug 04 2009 

More From Other Websites
5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015 Apr 18 2015
Idera to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
Idera to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
Here are 10 local biotechs investing heavily in their future Apr 10 2015
Idera draws short-term call buyers Apr 06 2015
Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell... Apr 01 2015
Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell... Apr 01 2015
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Mar 23 2015
IDERA PHARMACEUTICALS, INC. Financials Mar 18 2015
Idera reports 4Q loss Mar 12 2015
Idera reports 4Q loss Mar 12 2015
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Provides... Mar 12 2015
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Provides... Mar 12 2015
IDERA PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 12 2015
Idera to Present at Two Upcoming Investor Healthcare Conferences Feb 25 2015
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 25 2015
Idera to Present at Two Upcoming Investor Healthcare Conferences Feb 23 2015
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 19 2015
One Reason Idera Pharmaceuticals (IDRA) Stock is Up Today Feb 17 2015
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Feb 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK